Document is current

Article History

Received: 16 May 2019

Accepted: 28 August 2019

First Online: 21 October 2019

Ethics approval and consent to participate

: All patients provided written informed consent for participation in a clinical trial that was approved by the Institutional Review Board at the National Cancer Institute (ClinicalTrials ID: NCT01772004; NCI Clinical Trial ID: 13-C-0063).

: Not applicable (individual details with identifiers not presented).

: A.R. – None, other than the CRADA mentioned in the <i>Funding</i> section.C.R.H. – None, other than the CRADA mentioned in the <i>Funding</i> section.A.T. – None.A.L.M. – None.S.Pe. – None.G.O.S.C. – None.U.G. – None.A.B. – None.E.S. – None.R.A.M. – None.L.Y.B. – None.S.Pi. – None.R.N.D. – None.Y-T.T. - None.L.M.L. – None.K.C. – Dr. Chin discloses that he is an employee of EMD Serono.F.G. – Dr. Ginty reports that her employer, GE Global Research Corporation and its parent company, GE, is the developer of the Cell-DIVE multiplex in situ immunofluorescence analysis platform used for a portion of this study.A.S. – Dr. Sood reports that his employer, GE Global Research Corporation and its parent company, GE, is the developer of the Cell-DIVE multiplex in situ immunofluorescence analysis platform used for a portion of this study.S.M.H. – None.J.S. – None, other than the CRADA mentioned in the <i>Funding</i> section.R.H. – None.J.L.G. – None, other than the CRADA mentioned in the <i>Funding</i> section.